Hanmi Pharm will increase its value through the creation of innovative new drugs and substantial growth

President Jong-soo Woo is holding the 11th regular shareholders' meeting of Hanmi Pharmaceutical.

President Jong-soo Woo is holding the 11th regular shareholders’ meeting of Hanmi Pharmaceutical.

Hanmi Pharmaceutical(318,000 -0.16%)Announced that the 11th regular shareholders’ meeting was held on the 26th.

The shareholders’ meeting minimized physical contact between shareholders by introducing an electronic voting system in advance. In addition to basic quarantine measures such as heating checks and wearing masks, acrylic screens were installed in all seats where shareholders were seated.

At the shareholders’ meeting on the day, Hanmi Pharm reported major business performances, including sales of 1.75 trillion won, operating profit of 487 billion won, net profit of 18.8 billion won and investment in R&D of 2261 billion won last year. Shareholders’ consent was obtained on the agenda for reappointment of executive directors whose term of office expired and the limit of compensation for directors.

Woo Jong-soo, CEO of Hanmi Pharm, said, “Although there were difficulties in the Corona 19 situation, we are growing steadily with various achievements such as achieving No. 1 in the outpatient prescription market for 3 consecutive years, exporting new biopharmaceutical technologies, and domestic approval of Lolontis new drugs.” “We will do our best to increase shareholder value through profitable growth.”

Hanmi Science, a holding company of Hanmi Pharmaceutical Group(58,800 -0.51%)The 48th regular shareholders’ meeting was also held. Hanmi Science reported major business performances last year, including sales of 8574 billion won, operating profit of 33.2 billion won, and net profit of 22.7 billion won. The directors’ remuneration limit agenda was decided.

Jong-yoon Lim, CEO of Hanmi Science said, “We are creating innovative synergy effects through the organic convergence of affiliates that are achieving the best performance in each field.” “I will repay each and every shareholder who has invested in’value creation’.”

Reporter Minsoo Han [email protected]

Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution

Source